Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cov-RBD-scNP-001 Vaccine With or Without Adjuvant in Healthy Adults
NCT07902583Phase 1Not yet recruiting
- Sponsor
- Duke University
- Start
- Nov 2026
- Primary completion
- Oct 2027
01
Overview
Phase 1 trial of Cov-RBD-scNP-001 in coronavirus disease 2019 (COVID-19) (6 cohorts), sponsored by Duke University. Primary endpoints: Number of participants with solicited local and systemic reactogenicity events at Day 43, Number of participants with study product-related and unrelated unsolicited non-serious adverse events at Day 57 and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
Cov-RBD-scNP-001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07902583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902583.